Share Name Share Symbol Market Type Share ISIN Share Description
Microsaic Systems Plc LSE:MSYS London Ordinary Share GB00B547ZY09 ORD 0.01P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.005 -3.13% 0.155 7,494,940 08:21:55
Bid Price Offer Price High Price Low Price Open Price
0.15 0.16 0.16 0.155 0.16
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 0.20 -2.59 -0.52 9
Last Trade Time Trade Type Trade Size Trade Price Currency
14:27:43 O 200,000 0.15 GBX

Microsaic Systems (MSYS) Latest News

More Microsaic Systems News
Microsaic Systems Investors    Microsaic Systems Takeover Rumours

Microsaic Systems (MSYS) Discussions and Chat

Microsaic Systems Forums and Chat

Date Time Title Posts
29/11/202116:45Microsaic Systems - A Phoenix Rising from the Ashes216
23/8/202106:13Microsaic Systems - 20181,094
16/2/202113:37Microsaic Systems806
06/1/202119:18Microsaic - Another pump and dump disaster81
24/7/201811:24Microsaic - miniaturised chip-size scientific instruments11

Add a New Thread

Microsaic Systems (MSYS) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Microsaic Systems trades in real-time

Microsaic Systems (MSYS) Top Chat Posts

Microsaic Systems Daily Update: Microsaic Systems Plc is listed in the Software & Computer Services sector of the London Stock Exchange with ticker MSYS. The last closing price for Microsaic Systems was 0.16p.
Microsaic Systems Plc has a 4 week average price of 0.15p and a 12 week average price of 0.15p.
The 1 year high share price is 0.48p while the 1 year low share price is currently 0.10p.
There are currently 6,076,365,146 shares in issue and the average daily traded volume is 11,315,293 shares. The market capitalisation of Microsaic Systems Plc is £9,418,365.98.
barnes4: Hi all Have been doing a bit of research and am quite surprised at the rock bottom share price Is it the market doesn’t believe a word or are missing an opportunity?
david gruen: Microsaic Systems plc 12 November 2021 Microsaic Systems plc ("Microsaic" or the "Company") New compact screening platform for human and environmental health Microsaic (AIM: MSYS) announces the addition of a new technology capability to its platform, as part of the strategic transition from equipment only sales to remote detection and analysis of human diagnostics and environmental health monitoring. This latest addition to the platform is expected to launch in H1 2022. Mass Spectrometry ("MS") is often considered the gold standard analytical technique for laboratory-based diagnosis. Microsaic's compact technology allows for MS analysis at the point of need, providing the unique capability to detect a large range of chemical entities in Human Diagnostics and Environmental Monitoring. The latest addition to Microsaic's platform is the integration of the Company's compact MS technology with Gas Chromatography ("GC") and extends Microsaic's existing applications in Liquid Chromatography ("LC"). This combination will provide an extensive range of analysis required by end-users for chemical detection, for use in a combined market estimated to be worth over $1Bn*. Microsaic's platform now offers automated detection of organic chemicals in both non-volatile and volatile compounds such as therapeutics, antibiotics, pesticides, petrochemicals, and personal care products. The platform can be used in Human Diagnostics where measurements are increasingly being made in the doctor's clinic or during surgery, with applications including the real time monitoring of Therapeutic Drugs. Microsaic's technologies can also detect contaminants in soil and water in minutes and is well suited to front line environmental monitoring of chemicals of emerging concern ("CEC") at the point of need. Glenn Tracey, CEO of Microsaic, commented: "Our enhanced platform will provide us with a significant opportunity for screening in both Human Health and Environmental applications." "This transition to a data-centric and commercially focused company, strategically positions us at the core of addressing many global societal problems. Together, these advanced technologies and partnerships in Human and Environmental Health, established this year are expected to completely transform our business in 2022 ." Environmental legislation: The COP26 Summit is a reminder that legislation is being drafted in all key economies to address climate change aimed at protection against soil and water contamination. Critical to this, is the understanding of factors affecting the ecosystem so that mitigation can take place immediately and cataclysmic damage to the environment can be prevented. There is now clear demand for green, sustainable, and ecological technology, to serve real-time environmental monitoring and, at the same time, deliver "lab performance" on the front line. Microsaic's platform has been designed to satisfy that need perfectly. Digital Health Care Revolution: Additionally, trends towards delocalised health care continue, where diagnosis, treatment and monitoring are happening in the doctor's clinic, or during surgery itself. Microsaic's MCSP creates high-fidelity data in real-time, and provides insights and allows decisions to be made without delay and without the need for time-consuming referrals to specialists or A&E.
ragnarr: G Brandon recently did an interview on Proactive. Thought this might be of interest for MSYS holders. . KP: And what are these forever chemicals that you talk about . GB: They are not something that has been here forever, I mean they have really only been developed since about 1938, actually it is 1938 when Dupont were originally looking to test refrigerant chemicals and came across by accident the ability of a certain type of refrigerant that was the slipperiest that has ever seen and that it could actually contain…be preserved at very high heat, and we all know that in 1954, we don’t know the particular date, but we do know that around about that time Teflon was actually brought to the market, you know, you had your massive Teflon pots, pans everything was non-sticky. And unfortunately what happens is these chemicals are, they don’t fall, eventually the pan will become sticky and you will have to replace the pan. The reason why is because the chemicals come away, and they come away in foods that are cooked, they come away in…like for instance…the biggest issue was, you remember plastics, you could not put plastics into microwave, well with a coating of this all manufactured from these kind of long chain chemicals, its possible to have plastic in microwaves. Although that seems great, but the reality is, that transfers some of the chemicals onto your food. And 99 percent, unfortunately we are at that point, 99 percent of the population of the world actually has forever chemicals in them. I mean thats how prolific it has actually become and some of them are actually dangerous, cancerous chemicals, and in drinking water, they are pretty much pervasive at the moment and there is a move to realise, by the environmental protection agencies around the world that forever chemicals have to be managed a little bit better, and therefore they are looking at ways that they can reduce the potential of risk for forever chemicals, and again detection of those, you know sadly there are as many as…6000, ive seen 2800, 2900 but there is a database of nearly 6000 forever chemicals… and they are just everywhere (stutter) yeah..
david gruen: MSYS is the engine. DVRG provides some uses for this engine. MSYS can be the engine has many other applications. All the clues are there. Join the dots, and have a happy retirement. Looking forward to having a San Miguel with GB in Benidorm.
ragnarr: More great news from DVRG - clearly going places and MSYS will are in for the ride as well. DYI
david gruen: 27 October 2021 Microsaic Systems plc ("Microsaic" or the "Company") Launch of real-time monitoring workflows and services for scaling drug manufacture Microsaic (AIM: MSYS) is pleased to announce the immediate roll-out of its compact Mass Spectrometry ("MS") technology integrated with autosampler and separation technology, wrapped in closed-loop (automated) control software, for use in the scale-up and operation of drug manufacturing. These monitoring solutions are targeted at contract research and manufacturing organisations ("CRMO"), integration partners and biopharmaceutical companies who manufacture vaccines, therapeutics for major diseases such as chronic autoimmune diseases. This offering adds turn-key services to the bioprocessing industry, using compact Microsaic technology for monitoring levels of metabolites and proteins as part of wider workflows designed to: -- increase the efficiency of biotherapeutic development and manufacture; -- reduce batch failures; and, -- create the pathway to real-time data and analytics and [potential] optimisation of biopharmaceutical manufacture. These solutions can therefore reduce manufacturing scale-up time and costs, improve quality and reduce the cost of drug manufacture, while increasing the throughput from discovery and development and the quantity of approved drugs able to reach the market in the shortest time possible. The Company's small-footprint bio-reactor monitoring technology has already demonstrated the ability to track successfully all key parameters during biomanufacture (as announced on 2 July 2021), such as feedstocks, metabolites and now additionally the target proteins (for example, complex monoclonal antibody therapeutics) in real-time. Glenn Tracey, CEO of Microsaic, commented: " The accelerated development and scale-up of COVID-19 vaccines has shown what can be achieved by biopharmaceutical manufacturing. It has also emphasised the need to find ways to develop and manufacture life-changing drugs and therapies on a large scale, both quickly and reliably. These new monitoring solutions bring potentially game-changing capabilities to monitor the material aspects of bioproduction, in real time and at the point of need, and to address these critical manufacturing needs. Additionally, Microsaic brings its expertise in workflow customisation, set up, and software control and analytics. "This extension to our range of MS equipment and solutions to cover biologic molecules, alongside other gains in detection sensitivity, immediately widens the opportunities for revenues from multiple sectors in biopharmaceuticals, healthcare and environmental industries. We expect workflow service and installations to begin in H1 2022."
daveboy19: Share price as impressed as ever !
onehanded: Have NO investment here with MSYS, but today doing some research to see if I should. Fully invested in Deepverge. GB did confirm yesterday that MSYS is fully funded this year , which was one of my concerns of a placing soon. With that out of the way seems more attractive. Found a few good things.. MSYS is debt free Short Term Liabilities: MSYS's short term assets (£1.4M) exceed its short term liabilities (£238.3K). Long Term Liabilities: MSYS's short term assets (£1.4M) exceed its long term liabilities (£125.1K) Could be worth a small investment here.
city analyst1: Private investors would be wise to note the following: On July 08, 2021, on the IMC (Investor Meet Company) channel, Microsaic’s head honcho, Glenn Tracey, gave an unequivocally bullish response to a private investor’s question on the current share price. Using speech recognition software, and from 14:03mins to 15:40mins, I captured the entire dialogue verbatim. Here goes… PRIVATE INVESTOR “You’ve had a trail of good news recently showing a lot of traction since January. Do you think this is adequately reflected in the share price? GLENN TRACEY “I’m not surprised that question has come up. I mean, look at the news flow we’ve put out there; • We’re the first to market! • We’re the first in the world with an amazing way of getting biologics to market faster! • We’re about to get a medical licence in China and sell our product into hospitals, of which there are 33,000 in China alone! “Our news flow is month after month of really positive news.” “And yes, we’re absolutely seeing churn in the share price. But pretty much all of it is short term churn. I can say, there’s very little institutional churn.” “I think what we have to do is focus on the fundamentals of the business, which we are doing. There’s going to be more news coming out.” “I mean, this is a company that has had £30m invested in it! We’ve got a fantastic channel ahead of us. We’re bringing new products to market.” “You know, if you asked a CEO of any business, if their company was undervalued they are likely going to say yeah, of course they are. But, 0.25 of a pence, for this technology, and for this opportunity, for me is extremely undervalued. And hopefully soon, that share price will pop because the real value of this company is going to be seen.” Https://www.youtube.com/watch?v=m5B6QH5kR1Y Indiana poet, James Whitcomb Riley, once opined that, "If it looks like a duck, swims like a duck, and quacks like a duck, then it probably is a duck." In other words, MSYS is displaying all the signs of a winning technology stock on the verge of take-off. So my take on the company is simple: Against the backdrop of astonishing technological breakthroughs and commercial traction, the company is sporting a staggering risk-reward ratio and is, as a result, materially mispriced at 0.25pence per share (or £12.8m market cap). Thus, I fully concur with the CEO and expect the share price to pop sooner rather than later. AIMHO
david gruen: 06/07/2021 7:00am UK Regulatory (RNS & others) Microsaic Systems (LSE:MSYS) Intraday Stock Chart Tuesday 6 July 2021 Click Here for more Microsaic Systems Charts. TIDMMSYS RNS Number : 2415E Microsaic Systems plc 06 July 2021 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018) ("UK MAR"). 6 July 2021 Microsaic Systems plc ("Microsaic" or the "Company") Microsaic trading update for H1 2021 Unaudited revenues up 594% on H1 2020 and 52% on H1 2019, reflecting new business model Microsaic (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments is delighted to announce that a strategic change of business model early in 2021 has resulted in recovery of growth in revenues, increasing to GBP0.499m in H1 2021, significantly above H1 2020 and that of H1 2019, a pre-pandemic benchmark. First Half Highlights: -- Unaudited revenues of GBP0.499m o 594% increase over H1 2020 (GBP0.072m) and 52% over H1 2019 (GBP0.328m). -- January: transformative placing which raised GBP5.5m (gross), board changes and strategic shift away from independent development to a commercial strategy with external partners. -- Five key commercial hires to accelerate revenues on environmental detection of water contamination and in human health markets, delivering real-time on-site monitoring and data analytics with connected Internet of Things ("IoT"), AI and support services. -- March: commercial agreement with DeepVerge plc ("DeepVerge"; AIM: DVRG), through which Microsaic products and services are being deployed internationally in applications such as water monitoring of chemicals and pathogens, and in support of DeepVerge's rapidly growing Labskin division. -- May: initial shipments to a new Chinese partner to obtain a medical licence in China for real-time therapeutic monitoring of drugs with commercialisation (including service and reagents revenue sharing) expected in 2022. -- May: collaboration with Swansea University to combine real-time monitoring of environmental water using AI in determining the link between environmental chemical pollution and human health. -- June: further order from DeepVerge under the framework agreement Post Period Events: -- July: The world first demonstration of real-time monitoring of on-line production of biotherapeutic drugs such as vaccines and anti-cancer treatments using Process Analytical Technology within a Microsaic micro-engineered MS solution. Ongoing commercial developments -- Disruptive low-cost and mobile system to detect organic chemicals in water and wastewater adapted for in-field deployment. -- Detection of volatile contaminants in water, with product demonstration expected in H2 of this year. This significantly expands the reach of applications with mobile capability for environmental regulatory authorities. -- Multiple collaboration projects, including in-surgery cancer diagnostics, with the aim to secure commercial supply agreements with the potential to revolutionise surgical oncology interventions. Glenn Tracey, CEO of Microsaic Systems plc, commented: " I am thrilled to report this transformational performance for the first half of 2021, after the effects that the COVID-19 lockdown had on our customers, employees in 2020 and the financial strain this placed on the Company. The new commercial strategy of collaborating, partnering and revenue sharing has moved the Company away from equipment-only sales. We are now offering integrated real-time data analytics with AI alongside our mass spectroscopy hardware, providing complete solutions such as in-field environmental testing and on-site human diagnostics. The change of strategy and adjustment to a revenue sharing business model has demonstrated solid evidence of sales growth which is expected to continue into H2. Given the ongoing uncertainties over the effects of further waves of COVID-19 across multiple geographies, the Board remains cautious on short-term forecasting. Accordingly, we will consider whether it is appropriate to reinstate guidance to analysts after publication of the interim results, which is expected to take place during the autumn. However, prospects over the mid-term are looking more positive, with the encouraging first half results being more reflective of the Company's potential, and we look forward to our next scheduled performance update. " Related party transaction On 24 March 2021, the Company announced that it had entered into a non-exclusive Framework Services Agreement (the "Agreement") with DeepVerge. The multi-year Agreement provides for the supply by Microsaic to DeepVerge of miniaturised mass spectrometry equipment and services, across DeepVerge's sales, marketing, and distribution channels. The Agreement included an initial order of three units as well as a commitment to purchase further units in connection with the installation of pilot demonstration facilities at DeepVerge's York laboratories (together, the "Orders"). The Company has processed a further smaller purchase order from DeepVerge (the "Further Order") under the Agreement, supplying certain additional mass spectrometry equipment for quality and contamination detection in a range of markets including water and soil analysis. The value of the Further Order is approximately GBP72,000 and constitutes a related party transaction under Rule 13 of the AIM Rules. Additionally, Microsaic is loaning an additional item of equipment to DeepVerge for no consideration, to enable an early evaluation of certain technical aspects of its potential use. At the time of entering into the Agreement, the independent directors, being Glenn Tracey and Bevan Metcalf, considered, having consulted with the Company's nominated adviser, that the terms of the Agreement, were fair and reasonable insofar as the Company's shareholders are concerned. The independent directors also consider that the terms of the Further Order are consistent with the Agreement and with the terms of the initial Orders, and therefore they consider that the terms of the Further Order continue to be fair and reasonable insofar as shareholders are concerned.
Microsaic Systems share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Microsaic ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211207 16:28:34